UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase

The New England journal of medicine, 2016-11, Vol.375 (18), p.1717-1725

2016

Volltextzugriff (PDF)

Where there is inflammation, treatment may reduce disability progression – No

Multiple sclerosis, 2018-12, Vol.24 (14), p.1810-1812

2018

Volltextzugriff (PDF)

Multiple sclerosis lesions segmentation from multiple experts: The MICCAI 2016 challenge dataset

NeuroImage (Orlando, Fla.), 2021-12, Vol.244, p.118589-118589, Article 118589

2021

Volltextzugriff (PDF)

Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial

The Lancet (British edition), 2015-09, Vol.386 (9997), p.974-981

2015

Volltextzugriff (PDF)

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

The Lancet (British edition), 2007-08, Vol.370 (9585), p.389-397

2007

Volltextzugriff (PDF)

Cumulative effects of therapies on disability in relapsing multiple sclerosis

Multiple sclerosis, 2021-10, Vol.27 (11), p.1760-1770

2021

Volltextzugriff (PDF)

Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria"

Annals of neurology, 2005-12, Vol.58 (6), p.840-846

2005

Volltextzugriff (PDF)

Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study

Multiple sclerosis, 2023-05, Vol.29 (6), p.719-730

2023

Volltextzugriff (PDF)

Body mass index as a predictor of MS activity and progression among participants in BENEFIT

Multiple sclerosis, 2022-07, Vol.28 (8), p.1277-1285

2022

Volltextzugriff (PDF)

Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis

Multiple sclerosis, 2020-07, Vol.26 (8), p.924-935

2020

Volltextzugriff (PDF)

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

Lancet neurology, 2009-11, Vol.8 (11), p.987-997

2009

Volltextzugriff (PDF)

Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study

PloS one, 2015-07, Vol.10 (7), p.e0132033-e0132033

2015

Volltextzugriff (PDF)

Mass Cytometry Identifies Expansion of T-bet + B Cells and CD206 + Monocytes in Early Multiple Sclerosis

Frontiers in immunology, 2021-05, Vol.12, p.653577-653577

2021

Volltextzugriff (PDF)

The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges

Multiple sclerosis, 2021-03, Vol.27 (3), p.479-482

2021

Volltextzugriff (PDF)

High-dose biotin in progressive multiple sclerosis: A prospective study of 178 patients in routine clinical practice

Multiple sclerosis, 2020-12, Vol.26 (14), p.1898-1906

2020

Volltextzugriff (PDF)

Natalizumab in secondary progressive multiple sclerosis

Lancet neurology, 2018-05, Vol.17 (5), p.384-385

Edan, Gilles

2018

Volltextzugriff (PDF)

Differential item functioning of the Arm function in Multiple Sclerosis Questionnaire (AMSQ) by language, a study in six countries

Multiple sclerosis, 2021-01, Vol.27 (1), p.90-96

2021

Volltextzugriff (PDF)

Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis

The New England journal of medicine, 2007-01, Vol.356 (4), p.371-378

2007

Volltextzugriff (PDF)

Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple Sclerosis

Neurotherapeutics, 2021-01, Vol.18 (1), p.378-386

2021

Volltextzugriff (PDF)

Geographical Heterogeneity of Multiple Sclerosis Prevalence in France

PloS one, 2016-12, Vol.11 (12), p.e0167556-e0167556

2016

Volltextzugriff (PDF)

Escalation Versus Induction/High-Efficacy Treatment Strategies for Relapsing Multiple Sclerosis: Which is Best for Patients?

Drugs (New York, N.Y.), 2023-10, Vol.83 (15), p.1351-1363

2023

Volltextzugriff (PDF)

The TOTEM RRMS (Testosterone Treatment on neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis) trial: study protocol for a randomized, double-blind, placebo-controlled trial

Trials, 2020-06, Vol.21 (1), p.591-591, Article 591

2020

Volltextzugriff (PDF)

Focal and diffuse cervical spinal cord damage in patients with early relapsing–remitting MS: A multicentre magnetisation transfer ratio study

Multiple sclerosis, 2019-07, Vol.25 (8), p.1113-1123

2019

Volltextzugriff (PDF)

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials

Multiple sclerosis, 2019-04, Vol.25 (4), p.565-573

2019

Volltextzugriff (PDF)

1 – 25 von 298

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(271)
Mit Volltextzugriff
(236)

Publikationsform

Sprache

Englisch
(271)
Französisch
(28)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Multiple Sclerosis
(49)
Neurology
(42)
Revue Neurologique
(21)
Journal Of Neurology
(14)
European Journal Of Neurology
(10)
Multiple Sclerosis And Related Disorders
(8)
Brain
(7)
La Presse Médicale
(7)
Annals Of Neurology
(6)
Archives Of Neurology
(6)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase

Where there is inflammation, treatment may reduce disability progression – No

Multiple sclerosis lesions segmentation from multiple experts: The MICCAI 2016 challenge dataset

Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

Cumulative effects of therapies on disability in relapsing multiple sclerosis

Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria"

Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study

Body mass index as a predictor of MS activity and progression among participants in BENEFIT

Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study

Mass Cytometry Identifies Expansion of T-bet + B Cells and CD206 + Monocytes in Early Multiple Sclerosis

The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges

High-dose biotin in progressive multiple sclerosis: A prospective study of 178 patients in routine clinical practice

Natalizumab in secondary progressive multiple sclerosis

Differential item functioning of the Arm function in Multiple Sclerosis Questionnaire (AMSQ) by language, a study in six countries

Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis

Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple Sclerosis

Geographical Heterogeneity of Multiple Sclerosis Prevalence in France

Escalation Versus Induction/High-Efficacy Treatment Strategies for Relapsing Multiple Sclerosis: Which is Best for Patients?

The TOTEM RRMS (Testosterone Treatment on neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis) trial: study protocol for a randomized, double-blind, placebo-controlled trial

Focal and diffuse cervical spinal cord damage in patients with early relapsing–remitting MS: A multicentre magnetisation transfer ratio study

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials

Suchergebnisse filtern